Welcome to the Oncomine Blog
Evaluating NGS technologies for in-house comprehensive genomic profiling
11/13/2024 |
Research
In everyday practice, it is common for pathology labs to evaluate >50% cytological specimens across solid tumors especially in lung and pancreatic...
-
Breakthrough Device Designation for Oncomine Dx Precision Test Provides Insights into Brain Tumors Fueled by a Common Genetic Mutation
Philip Scard knew immediately and intimately that the June 15 news release from Thermo Fisher Scient... -
The Impact of NGS in Hematology-Oncology
In aggressive forms of cancer such as acute myeloid leukemia (AML), accurate diagnosis is needed as ... -
Comprehensive Biomarker Testing Reveals RET Alteration to Change Course of NSCLC Patient’s Treatment Options and Survival Outcome
It’s been a tough road for Melissa Crouse, sometimes almost deadly. She had a lobe of her left lung ... -
Building a Case for In-House Next Generation Sequencing
Diagnostics lab team demonstrates how insourcing NGS makes sound financial sense and helps deliver c... -
Q2 Solutions Eyes Genexus System as its Game-Changing Solution for Global Clinical Trial Services
When it comes to supporting clinical trials, having a global footprint is simply not enough for cont...